AbCellera Biologics, Inc. ABCL 深 滬
交易中 06-25 10:39:43 美东时间
6.3436
+0.314
+5.20%
華盛通- 最 高6.445
- 今 開6.10
- 成交量 284.89万股
- 最 低 6.09
- 昨 收 6.03
- 總市值 19.37亿
- 52周最高 6.79
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 2.745
- 委 比 0.00%
- 總股本 3.05亿
- 歷史最高 71.91
- 量 比 2.79
- 振 幅 5.89%
- 歷史最低 1.8906
- 每 手 1
- 風險率 0.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AbCellera, Jazz Partner on Next-Generation Cancer Antibodies
AbCellera Biologics ( ($ABCL) ) has issued an update. On June 17, 2026, Jazz Ph...
06-18 00:57
Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop Next-Gen T-Cell Engaging Multispecific Antibodies
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop Jazz has the exclusive option to develop and commercialize therapeutic antibodies resulting from the col...
06-17 19:11
These low-priced stocks are flashing overbought signals
Stocks trading below $10 often attract retail investors looking for high-growth opportunities at relatively low entry prices. However, many of these low-priced equities can become overheated during st...
06-02 18:23
美股夜盘 | 泰勒·莫里森家涨20.00%，Hyperliquid Strategies, Inc涨19.32%
泰勒·莫里森家涨20.00%；Hyperliquid Strategies, Inc涨19.32%；Revolution Medicines涨17.75%
06-01 13:01
美股夜盘 | 泰勒·莫里森家涨20.00%，Hyperliquid Strategies, Inc涨17.32%
泰勒·莫里森家涨20.00%；Hyperliquid Strategies, Inc涨17.32%；Summit Therapeutics Inc涨16.02%
06-01 10:01
电话会总结 ｜ AbCellera(ABCL)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据AbCellera业绩会实录，以下是2026年第一季度财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 第一季度营收800万美元，同比增长100%（2025年同期为400万美元），主要来源为研究费收入。 **盈利状况：** 净亏损4300万美元，同比收窄6.5%（2025年同期净亏损4600万美元）。每股亏损0.14美元（基本和稀释）。 **现金流状况：** 经营活动现金流出3400万美元；净现金流出3000万美元。期末现金及等价物约5.3亿美元，现金、现金等价物及有价证券总计5.31亿美元。 **费用控制：** 研发费用4700万美
05-12 12:26
AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is unchanged from the same period last year. The company reported
05-12 04:08
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Cantor Fitzgerald Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $7
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $7.
05-06 01:45
